Bell Potter upgrade 16 April
Upgrade to $5.80 due to Covid ARDS.
Analyst admits to very conservative assumptions re this new indication. Revenues risk adjusted at 50% until FDA approval would allow removal of that.
Modelling for Covid ARDS is for US only. Nil for EU.
No allowance made for the several other causes of ARDS and pulmonary fibrosis that Rem-L might treat, as noted by several posters here.
Analyst allows considerable upside to valuation and potential re-rating via several near term catalysts in CY20.
Cell Therapy News/Articles, page-1648
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |